In vitro studies demonstrate that rosiglitazone is predominantly metabolised by CYP2C8, with CYP2C9 as only a minor pathway.
Los estudios in vitro demuestran que rosiglitazona se metaboliza principalmente por el CYP2C8, mientras que el CYP2C9 representa una vía minoritaria.